AAP News Vol. 1 No. 4 April 1985, p. 1
© 1985 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Next Article 

AAP announces support for intent of bill requiring aspirin-Reye labels

Saying that there is "more reason than ever to warn the public, especially young adolescents," about the link between aspirin use and Reye Syndrome, the Academy last month announced it "support(s) the intent" of federal legislation which would require warning labels on all aspirin products.

At a March 15 hearing held by a congressional panel to consider the legislation, AAP Committee on Drugs Chairman Albert Pruitt, M.D., questioned the effectiveness of a voluntary labeling program instituted in January by U.S. Health and Human Services (HHS) Secretary Margaret M. Heckler. Aspirin makers agreed to the voluntary program after a pilot study conducted by the U.S. Public Health Service (USPHS) showed a strong link between aspirin use and Reye Syndrome.